References
- Kim MH, Park SH, Cho HJ, Choi JS, Kim JO, Ahn HK, Shin JY. Kim MY,
Yang JH. Threshold of nuchal translucency for the detection of
chromosomal aberration: comparison of different cutoffs. J Korean Med
Sci 2006;21:11-14.
- Committee Opinion No.640: Cell-free DNA screening for fetal
aneuploidy. Obstet Gynecol 2015;126:e31-37.
- Souka AP, Von Kaisenberg CS, Hyett JA, Sonek JD, Nicolaides KH.
Increased nuchal translucency with normal karyotype. Am J Obstet
Gynecol 2005;192:1005-1021.
- Nicolaides KH, Azar G, Byrne D, Mansur C, Marks K. Fetal nuchal
translucency: ultrasound screening for chromosomal defects in first
trimester of pregnancy. BMJ 1992;304:867-869.
- Bekker MN, Haak MC, Rekoert-Hollander M, Twisk J, Van Vugt JM.
Increased nuchal translucency and distended jugular lymphatic sacs on
first-trimester ultrasound. Ultrasound Obstet Gynecol
2005;25:239–245.
- Nicolaides KH. First-trimester screening for chromosomal
abnormalities. Semin Perinatol 2005;29:190–194.
- Bilardo CM, Pajkrt E, de Graaf I, Mol BW, Bleker OP. Outcome of
fetuses with enlarged nuchaltranslucency and normal karyotype.
Ultrasound Obstet Gynecol 1998;11:401–406.
- Kim SY, Lee SM, Jun JK, Han YJ, Kim MH, Shim JY, Lee MY, Oh SY, Lee J.
Kim SH, Cha DH, Cho GJ, Kwon HS, Kim BJ, Park MH, Cho HY, Ko HS, Ahn
J, Ryu HM. Prospective observations study protocol to investigate
cost-effectiveness of various prenatal test strategies after the
introduction of noninvasive prenatal testing. BMC Pregnancy Childbirth
2018;18:307.
- Fetal Medicine Foundation.
https://fetalmedicine.org/nuchal-translucency-scan/[12September
2010].
- Wright D, Kagan KO, Molina FS, Gazzoni A, Nicolaides KH. A mixture
model of nuchal translucency thickness in screening for chromosomal
defects. Ultrasound Obstet Gynecol 2008; 31:376–383.
- Seror
V, L’Haridon O, Bussières
L, Malan
V, Fries
N, Vekemans
M, Salomon
LJ, Ville
Y; SAFE
21 Study Group.Women’s Attitudes Toward Invasive and Noninvasive
Testing When Facing a High Risk of Fetal Down Syndrome. JAMA Netw Open
2019;2:e191062.
- Berger VK, Norton
ME, Sparks
TN, Flessel
M, Baer
RJ, Currier
RJ. The utility of nuchal translucency ultrasound in identifying rare
chromosomal abnormalities not detectable by cell-free DNA screening.
Prenat Diagn 2020;40:185-190.
- Nicolaides KH. Nuchal translucency and other
first-trimestersonographic markers of chromosomal abnormalities. Am J
Obstet Gynecol 2004;191:45–67.
- Souka AP, Snijders RJ, Novakov A, Soares W, Nicolaides KH. Defects and
syndromes in chromosomally normal fetuses withincreased nuchal
translucency thickness at 10–14 weeks ofgestation. Ultrasound Obstet
Gynecol 1998;11:391–400.
- Kagan KO, Avgidou K, Molina FS, Gajewska K, Nicolaides KH. Relation
between increased fetal nuchal translucency thickness and chromosomal
defects. Obstet Gynecol 2006;107: 6–10.
- ACOG Practice Bulletin No. 163: Screening for fetal aneuploidy. Obstet
Gynecol 2016; 127:e123-137.
- Shakoor
S,
Dileep
D,
Tirmizi
S,
Rashid
S,
Amin
Y,
Munim
S.Increased nuchal translucency and adverse pregnancy outcomes. J
Matern Fetal Neonatal Med 2017;30:1760-1763.
- Lichtenbelt KD, Diemel BD, Koster MP, Manten GT, Siljee J,
Schuring-Blom GH, Page-Christiaens GC. Detection of fetal chromosomal
anomalies: does nuchal translucency measurement have added value in
the era of non-invasive prenatal testing? Prenat Diagn 2015;
35:663–668.
- Srebniak
MI,
de
Wit MC,
Diderich
KE,
Govaerts
LC,
Joosten
M,
Knapen
MF,Bos
MJ,
Looye-Bruinsma
GA,
Koningen
M,
Go
AT,
Galjaard
RJ,
Van
Opstal D. Enlarged NT (≥3.5 mm) in the first trimester - not all
chromosome aberrations can be detected by NIPT. Mol Cytogenet
2016;9:69.
- Khalil A, Mahmoodian N, Kulkarni A,
Homfray
T,
Papageorghiou
A,
Bhide
A, Thilaganathan B. Estimation of detection rates of aneuploidy in
high-risk pregnancy using an approach based on nuchal translucency and
non-invasive prenatal testing: a cohort study. Fetal Diagn Ther
2015;38:254-261.
- Bardi
F, Bosschieter PFN, Verheij
JBGM, Go
ATJI, Haak MC, Bekker MN,
Sikkel
E,
Coumans
ABC,
Pajkrt
E,
Bilardo
CM. Is there still a role for nuchal translucency measurement in the
changing paradigm of the changing paradigm of first trimester
screening?
Prenat
Diagn 2020;40:197-205.
- Syngelaki A, Pergament E, Homfray T,
Akolekar
R,
Nicolaides
KH. Replacing the combined test by cell-free DNA testing in screening
for trisomies 21, 18 and 13: impact on the diagnosis of other
chromosomal abnormalities. Fetal Diagn Ther 2014;35:174–84.
- Gil
MM,
Accurti
V,
Santacruz
B,
Plana
MN,
Nicolaides
KH.Analysis of cell-free DNA in maternal blood in screening for
aneuploidies: updated meta-analysis. Ultrasound Obstet Gynecol
2017;50:302-314.
- Ghi T, Huggon IC, Zosmer N, Nicolaides KH. Incidence of major
structural cardiac defects associated with increased nuchal
translucency but normal karyotype. Ultrasound Obstet Gynecol
2001;18:610-614.
- Atzei
A,
Gajewska
K,
Huggon
IC,
Allan
L,
Nicolaides
KH. Relationship between nuchal translucency thickness and prevalence
of major cardiac defects in fetuses with normal karyotype. Ultrasound
Obstet Gynecol 2005;26:154-157.
- LJ Salomon, A Sotiriadis, CB Wulff, A Odibo, R Akolekar. Risk of
miscarriage following amniocentesis or chorionic villus sampling:
systematic review of literature and updated meta‐analysis. Ultrasound
Obstet Gynecol 2019;54:442-451.